IP Library Granted Patent US 11,433,073
Granted Patent B2
US 11,433,073 · App. 17/580,755 · Granted Sep 6, 2022

Compositions and methods for the prevention and treatment of hearing loss

Inventors: Jian Zuo (Omaha, NE); Tai Teitz (Omaha, NE)
Assignee: Ting Therapeutics LLC
A61K31/519A61K31/437A61K31/4439A61K31/4709A61K31/506A61P27/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,433,073
App. No.
17/580,755
Granted
Sep 6, 2022
Kind
B2
Abstract

Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described.

Claims (9)

1. A method to prevent cisplatin-induced hearing loss comprising: orally administering to animal in need thereof a pharmaceutical composition comprised of: a sufficient amount of Dabrafenib to prevent hearing loss due to cisplatin treatment, wherein the sufficient amount of Dabrafenib is 100 mg/kg.

2. The method of claim 1 , comprising: orally co-administering to animal in need thereof a pharmaceutical composition comprised of: a sufficient amount of Dabrafenib and Trametinib to prevent hearing loss due to cisplatin treatment, wherein the sufficient amount of Trametinib is 2 mg/kg twice daily.

3. A method to prevent noise induced hearing loss comprising: orally administering to an animal in need thereof a pharmaceutical composition comprised of: a sufficient amount of Dabrafenib to prevent hearing loss due to a noise exposure, wherein the sufficient amount of Dabrafenib is 100 mg/kg twice daily.

4. The method of claim 3 , wherein Dabrafenib is administered 45 minutes before the noise exposure.

5. The method of claim 3 , wherein Dabrafenib is administered for three days after the noise exposure.

6. The method of claim 3 , comprising co-administering a pharmaceutical composition comprised of: a sufficient amount of AZD5438 to prevent hearing loss due to a noise exposure.

7. The method of claim 3 , wherein Dabrafenib is administered 45 minutes before the noise exposure, wherein the sufficient amount of Dabrafenib is 60 mg/kg twice daily.

8. A method to prevent noise induced hearing loss comprising: orally administering to an animal in need thereof a pharmaceutical composition comprised of: a sufficient amount of Dabrafenib to prevent hearing loss due to a noise exposure wherein the sufficient amount of Dabrafenib is 60 mg/kg twice daily and administering a sufficient amount of AZD5438.

9. The method of claim 8 , wherein the sufficient amount of AZD5438 is 35 mg/kg twice daily.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2024
From: ZUO, JIAN; TEITZ, TAL
To: TING THERAPEUTICS LLC
Reel/Frame 069018/0402 →
MERGER AND CHANGE OF NAME Recorded Oct 9, 2024
From: TING THERAPEUTICS LLC; TING THERAPEUTICS, INC.
To: TING THERAPEUTICS, INC.
Reel/Frame 069138/0580 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2022
From: JIAN, ZUO; TEITZ, TAL
To: TING THERAPEUTICS, LLC
Reel/Frame 058724/0170 →
Continuity (3)
Continuation PCTUS2020063595 · Dec 7, 2020
Provisional Application 62947059 · Dec 12, 2019
Related Publication 20220133730A1 · May 5, 2022
Cited By (1)
US 12,427,149